The Group has possessed clinical demand-oriented product identification and project management capabilities, proven clinical development and commercialization capabilities, and substantial cash flow. Leveraging core advantages and driven by an innovation strategy of “Collaborative R&D and In-house R&D”, we have collaborated extensively with global innovation forces, to continuously deploy global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promote their clinical development and commercialization processes, empowering the continuous transformation of scientific research outcomes into clinical practices and benefiting numerous patients.
*Best-in-class: innovative products with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems
Innovative Pipeline Products
projects have been prepared for/are processing their registrational clinical trials, mainly randomized controlled trials (RCT).
Approved for Marketing in China
*Unless otherwise stated, the above data are as at June 30, 2024
# In July 2024, innovative drug METOJECT (Methotrexate Injection) was approved for marketing in China with addition indication of active rheumatoid arthritis in adult patients.
We acquire innovative products that are in the mid- and late-phase of clinical development or have been approved for marketing. CMS is responsible for clinical development, registration and commercialization of products in China and other authorized countries/regions, in order to improve the patient access of innovative medicine.
CMS is responsible for clinical development, registration and commercialization in China and other authorized countries/regions. This allows the biotech companies to focus on drug discovery and preclinical studies, thereby improving R&D efficiency and accelerate the commercialization of domestic innovative products.
For novel or popular targets in our therapeutic fields of focus, CMS manages the entire life cycle of innovative medicines itself, whilst also giving CMS ownership of the product rights globally.
We have established an in-house clinical development system focused on the four key components: medical, clinical, pharmacovigilance and quality assurance. The process is overseen to provide high-level confidence that the medical strategy is rational, clinical operations are effective and compliant, and product safety risks are controllable.
Proven clinical enrollment capability:
*Tildrakizumab Solution for Injection- Completed
enrollment of all the 220 subjects within 2.5 months (including the Chinese Spring Festival
holidays)
*Methylthioninium Chloride Enteric-coated
Sustained-release Tablets- Completed enrollment of all the 1,800 subjects within 6 months (including the
Chinese Spring Festival holidays)
